<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840901</url>
  </required_header>
  <id_info>
    <org_study_id>17955</org_study_id>
    <secondary_id>J2T-MC-KGBG</secondary_id>
    <nct_id>NCT04840901</nct_id>
  </id_info>
  <brief_title>A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose Bioequivalence Study of Injections of Lebrikizumab Using a 2-mL Pre-Filled Syringe With Needle Safety Device and an Investigational 2-mL Autoinjector in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that&#xD;
      gets into the blood stream and how long it takes the body to get rid of lebrikizumab&#xD;
      (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe&#xD;
      with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be&#xD;
      evaluated. The study will last up to 102 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">January 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lebrikizumab</measure>
    <time_frame>Predose up to 99 days postdose</time_frame>
    <description>PK: (Cmax) of Lebrikizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Lebrikizumab</measure>
    <time_frame>Predose up to 99 days postdose</time_frame>
    <description>PK: AUC[0-∞] of Lebrikizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab</measure>
    <time_frame>Predose up to 99 days postdose</time_frame>
    <description>PK: AUC[0-tlast] of Lebrikizumab</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lebrikizumab - Pre-Filled Syringe with Needle Safety Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lebrikizumab administered subcutaneously (SC) via pre-filled syringe with needle safety device (PFS-NSD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lebrikizumab - Autoinjector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lebrikizumab administered SC via autoinjector (AI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lebrikizumab</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Lebrikizumab - Autoinjector</arm_group_label>
    <arm_group_label>Lebrikizumab - Pre-Filled Syringe with Needle Safety Device</arm_group_label>
    <other_name>LY3650150</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are Overtly healthy males or nonpregnant females of childbearing or non-childbearing&#xD;
             potential as determined through medical evaluation.&#xD;
&#xD;
          -  Agree not to donate blood or plasma until after the end of their participation in the&#xD;
             study&#xD;
&#xD;
          -  Have a body mass index (BMI) within the range 18.0 to 32.0 kilograms per meter squared&#xD;
             (kg/m²)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are females who are pregnant or lactating.&#xD;
&#xD;
          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs&#xD;
&#xD;
          -  Have a history or presence of psychiatric disorders&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus infection.&#xD;
&#xD;
          -  Show evidence of hepatitis C and/or hepatitis B&#xD;
&#xD;
          -  Medical history of allergic reaction to humanized monoclonal antibodies&#xD;
&#xD;
          -  Have had lymphoma, leukemia, or any malignancy within the past 5 years except for&#xD;
             basal cell or squamous epithelial carcinomas of the skin that have been resected with&#xD;
             no evidence of metastatic disease for 3 years.&#xD;
&#xD;
          -  Are currently enrolled in any other clinical study involving an investigational&#xD;
             product or any other type of medical research judged not to be scientifically or&#xD;
             medically compatible with this study.&#xD;
&#xD;
          -  Smoke more than 10 cigarettes per day or the equivalent including electronic&#xD;
             cigarettes or are unable to abide by CRU smoking restrictions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LabCorp CRU, Inc.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LabCorp CRU, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

